{"id":47987,"date":"2022-09-06T09:01:40","date_gmt":"2022-09-06T07:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/"},"modified":"2022-09-06T09:01:40","modified_gmt":"2022-09-06T07:01:40","slug":"dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/","title":{"rendered":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG"},"content":{"rendered":"
\n

TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin<\/a>–Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Geldmacher will be responsible for shaping Lysando’s strategy and identifying areas where Lysando’s technology can add the most value. He will actively contribute to bringing the Artilysin\u00ae technology to market.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nPrior to joining Lysando AG, Dr. Geldmacher has been part of the consulting firm McKinsey & Company for almost nine years. As Associate Partner in the Healthcare and Life Sciences Practice he supported his clients in strategy projects, large-scale transformations as well as M&A-related work. In this capacity he has chaperoned Lysando AG and the Artilysin\u00ae technology for the past four years.\n<\/p>\n

\n“Dr. Geldmacher is establishing entirely new functions and processes in our company. With his medical background, a university degree in Molecular Medicine plus the extensive experience in management consulting, he is the perfect fit for Lysando,” says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “With his expertise and skill set he will play a key role in shaping the future development of our company and further drive our success.”\n<\/p>\n

\nDr. Fabian Geldmacher assumed the position of Director Strategy & Business Development on June 1, 2022.\n<\/p>\n

\n“My interest in the fight against infectious diseases has first been sparked as a teenager. This passion has stayed with me ever since and at Lysando AG I am now in a position to contribute to combatting the rise of resistant bacteria on a global scale”, says Dr. Geldmacher. “I look forward to the journey ahead and am excited about the opportunity to change the world for the better.”\n<\/p>\n

\nAbout Lysando AG<\/b>\n<\/p>\n

\nLysando AG is the market leader for antimicrobial proteins, so-called Artilysin\u00aes. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin\u00aes constitute an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics.\n<\/p>\n

\nLysando AG’s research facility is Lysando Innovations Lab GmbH located in Regensburg’s BioPark. BioPark Regensburg fosters companies in biotechnology, medical technology, diagnostics & analytics as well as the local healthcare management.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nVerena Schossmann
\n
+41(0)79 211 83 42
\n
Verena.Schossmann@lysando.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin–Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Geldmacher will be responsible for shaping Lysando’s strategy and identifying areas where Lysando’s technology can add the most value. He … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47987","6":"format-standard","7":"category-industry"},"yoast_head":"\nDr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin–Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Geldmacher will be responsible for shaping Lysando’s strategy and identifying areas where Lysando’s technology can add the most value. He ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T07:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG\",\"datePublished\":\"2022-09-06T07:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005285\\\/en\\\/1561212\\\/21\\\/Fabian_Geldmacher.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/\",\"name\":\"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005285\\\/en\\\/1561212\\\/21\\\/Fabian_Geldmacher.jpg\",\"datePublished\":\"2022-09-06T07:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005285\\\/en\\\/1561212\\\/21\\\/Fabian_Geldmacher.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220906005285\\\/en\\\/1561212\\\/21\\\/Fabian_Geldmacher.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend","og_description":"TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin–Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Geldmacher will be responsible for shaping Lysando’s strategy and identifying areas where Lysando’s technology can add the most value. He ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-06T07:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG","datePublished":"2022-09-06T07:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/","url":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/","name":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg","datePublished":"2022-09-06T07:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220906005285\/en\/1561212\/21\/Fabian_Geldmacher.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dr-fabian-geldmacher-is-director-strategy-business-development-of-lysando-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47987"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47987\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}